NCT06452277 2026-04-17
SOHO-02
Bayer
Phase 3 Recruiting
Clinical Trials
22 trialsNCT05099172 2026-04-14
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
Phase 1/2 Active not recruiting
NCT06434103 2026-04-08
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Withdrawn
NCT06868732 2026-03-30
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Recruiting
NCT06269133 2025-08-27
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Regeneron Pharmaceuticals
Active not recruiting
NCT02582125 2025-03-24
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Ono Pharmaceutical Co. Ltd
Phase 2 Completed
NCT05215067 2025-03-12
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
Akeso
Phase 2 Active not recruiting
NCT06823245 2025-02-12
Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06775483 2025-01-15
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Not yet recruiting
NCT02108964 2024-12-11
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Novartis
Phase 1/2 Completed
NCT06585059 2024-09-05
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT06329895 2024-07-05
A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants
Bayer
Phase 1 Completed
NCT06378658 2024-07-05
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
Bayer
Phase 1 Completed
NCT06360211 2024-07-03
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants
Bayer
Phase 1 Completed
NCT06221475 2024-06-28
A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants
Bayer
Phase 1 Completed
NCT04818333 2024-06-13
A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Active not recruiting
NCT05420220 2024-05-01
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Recruiting
NCT05482568 2023-10-16
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT05001724 2023-04-25
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2/3 Terminated
NCT03693547 2023-01-10
Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Completed
NCT05416775 2022-08-19
Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT03856697 2019-02-27
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase 3 Unknown